Major new developments in the race for a COVID-19 vaccine are driving investors to reevaluate their positions.
News & Analysis: Sorrento Therapeutics
Its coronavirus programs may just save this cancer-focused biopharmaceutical from bankruptcy, but how risky is its stock?
A shocking announcement out of Russia sent shares of companies working on COVID-19 vaccines and treatments sharply lower.
The biotech promises to help end the coronavirus pandemic.
Hint: Only one of these stocks is a strong buy.
Analysts are intrigued by the biopharmaceutical company's new coronavirus test.
The biotech has a new coronavirus test that could see broad-scale usage.
A good day for the stock market is translating into a good day for the biotech.
Sorrento intends to acquire SmartPharm to develop its pipeline of gene-encoded antibodies to treat COVID-19 and cancer.
The biotech plans to make an acquisition for an undisclosed sum.